Curve.
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
NEW DIMENSIONS IN VACCINOLOGY: A NEW INSIGHT
D Tomar, V Chattree, V Tripathi, A A Khan, A R Bakshi and D N Rao
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi-110029
ABSTRACT
The development of vaccines to prevent infectious diseases has been one of the most important
contributions of biomedical sciences. Increasing understanding in biochemistry, molecular biology,
molecular genetics and related fields have provided an opportunity for the development of new
generation vaccines that are based on rational design approaches. This is possible because of
proper understanding of the microbial-genetics, biochemistry, host-pathogen interaction and recent
developments in molecular immunology. Another important improvement made in the quality of
vaccine production is the incorporation of immunomodulators or adjuvants with modified delivery
vehicles viz liposomes, Iscoms and microspheres apart from alum being used as a gold standard.
This article reviews the art of vaccination from Jenner period to present day context highlighting all
the developments made at each stage of the vaccine development. Various criteria have been
discussed regarding the selection of epitopes that expand B & T cells, its linkage with other
accessory cells of the immune system, means to overcome MHC linked immune
unresponsiveness, enhanced antigen processing and presentations that specially induce either
helper or cytotoxic or mucosal immune responses were critically discussed.
KEY WORDS
Peptide, Vaccine, Epitope, Antigen, Antibody, MHC, Adjuvant, Liposomes, Iscoms, and Microsphere
INTRODUCTION
Ever since the time of Jenner and Pasteur, vaccination
has been accepted as a part of life and constitutes
one of the most successful achievements in the field
of immunology. In spite of its imperfections, vaccination
remains the best answer to infectious diseases. The
art of deliberate immunization against infections has
of course been practiced for centuries, but the
mechanisms of protective immunity were not fully
appreciated until the advent of modern immunology.
With the discoveries of newer technologies and greater
understanding of the molecular biology of pathogens,
the conventional empirical approaches to vaccine
development have given way to more rational vaccine
design. Immunoprophylaxis through vaccination now
offers the prospect of substantially reducing the
mortality caused by microbial pathogens to human
race. A prophylactic vaccine aims to elicit immune
effector elements such as circulating antibodies and
various antigen specific memory lymphocytes. These
host elements are readily available for immediate
neutralization of the pathogen upon entry or for
production of cytotoxic molecules for destroying the
Author for correspondence
Dr. DN Rao
Department of Biochemistry, All India Institute of
Medical Sciences, New Delhi-110029
E-mail : dnrao113@hotmail.com
Indian Journal of Clinical Biochemistry, 2005
infected cells. Rational vaccine design requires
sensible formulated adjuvants. Adjuvant modulated
antigen structures and associated immunological
pathways therefore contribute to a better general
understanding of immune effector mechanism(s) but
eventually leads to more predictable efficacy.
Depending on the types of the disease, vaccine has to
fulfill a number of criterions. These may include an
early onset of immunity, long duration of effector
response through memory cells, the need to avoid
booster immunizations in order to reduce the cost of
vaccine and easy availability to mankind. Most of these
features are strongly dependent on the choice of
adjuvant.
This article briefly reviews the work on vaccine
development from the past to the present with special
emphasis on the work done in our laboratory and by
others in the field of synthetic peptide vaccines starting
from the identification of protective immunogen (s) and
delineating the B& T cell determinants using
algorithmic predictions followed by in vivo conformation
and their effectiveness in eliciting humoral as well as
cellular responses using immunoadjuvants or
immunostimulators or immunomodulators with
modified delivery vehicles with respect to various
infectious diseases. The discussion includes the new
approaches being explored in this field to increase the
immunogenicity of the peptides by better vaccine design
opted by scientists across the globe.
213
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
History, from Past to the Present
“Never in the history of human progress has a better
and cheaper method of preventing illness been
developed than immunization at its best”. This
statement by Edsall in 1963 reflects the success of
vaccines against diseases such as smallpox,
poliomyelitis, measles, rabies, yellow fever, diphtheria
and tetanus. The story of vaccinology began with
Jenner in 1796 in his demonstration of the scientific
principles and realities for preventing small pox by prior
infection with the related but less virulent cowpox virus
(1). The century that followed this primary event was
marked with trial and error together with a series of
new technologies and discoveries paving the path for
present knowledge in vaccine design. Table 1 shows
the vaccines licensed from the time of Jenner till date
and table 2 shows the strategies for development of
non-living vaccines with tables 3 and 4 showing the
principal vaccine targets by and beyond 2005.The
earliest vaccines were derived from killed pathogenic
organism or subunit of the pathogenic organism. This
is followed by live or attenuated virus or bacteria that
do not cause disease but have been derived from the
pathogenic parent organism. The killed or inactivated
vaccines are made from virulent pathogens by
destroying their infectivity to ensure the retention of full
immunogenicity. These vaccines are relatively safe but
however require periodic boosting to cope up flagging
immunity. The era for live virus vaccines was made
possible by the breakthrough in cell culture technology
by Enders, Weller and Robbins which opened the way
to the first and highly successful killed Salk (2) and live
Sabin (3) vaccines against poliomyelitis that were
introduced in 1960’s. During this time, the infected
organs of animals, embryonated chick eggs and
primitive cell cultures of animal tissues were used to
grow viruses for live attenuated and killed virus
vaccines and whole cell bacteria and their secreted
toxins were used in preparing vaccines against
disease caused by them. Purified viral proteins or their
subunits, and bacterial toxoids have certainly
diminished the incidence of morbidity and mortality of
a large number of infectious diseases, but their use is
still associated with several major problems like
excessive reactogenicity followed by serious delayed
type hypersensitivity reactions as observed in earlier
measles vaccine. Attenuation is generally achieved by
growing the pathogens in an ‘unnatural’ host
(passage); less commonly, known viruses have been
adapted to grow at a temperature lower than normal
(cold-adaptation) or have been rendered temperaturesensitive.
For inactivation, the pathogens are either subjected to
autoclaving or fixed by agents such as formalin, bpropiolactone or more recently an imine. However,
such vaccines may elicit side effects, which are
frequently unacceptably harmful to the hosts. Even with
Indian Journal of Clinical Biochemistry, 2005
the highly successful products such as the attenuated
Sabin poliovirus or killed Salk poliovirus vaccine, or
smallpox vaccines, there are a small but significant
number of post-vaccination incidents. Killed vaccines
may also present problems in that there is always the
chance of some infectious pathogens surviving the
inactivation process. Another problem is the constant
evolution of some viruses into new strains with different
serological specificity and sometimes viruses may
produce oncogenic initiation. Thus, there is a need for
new generation of molecularly defined vaccines, which
would induce the desirable immune responses
capable of controlling particular infectious agents. This
phenomenon is even more severe in parasites /
viruses that rapidly alter their antigenic structures as
seen by the failure of protection of the influenza vaccine
(4) or recently with HIV virus. In spite of their remarkable
efficacy, vaccines based on the pathogen itself may
sometimes lead to safety hazards. This indicates that
certain parts of the pathogen actually induce some
undesirable responses and should be eliminated from
the vaccine formulations in order to obtain maximum
efficacy. Many pathogens are virtually impossible to
culture outside their natural host for eg. Hepatitis B
virus and bacterium that causes leprosy have never
been grown in vitro although they can be propagated
in animal models. Consequently, it is not possible to
generate live attenuated or inactivated vaccines
culturing the agents. Attempts to produce sufficient
quantities of either the organism or antigens for malaria
research from in vitro cultures have not been very
successful. Even if adequate quantities of malarial
parasite can be obtained from in vitro cultures, the use
of such blood derived malarial products for vaccination
carries the risk of transmitting infectious agents such
as HIV and hepatitis virus (5). Recombinant DNA
technology allows the transfer of genetic information
from these fastidious organisms to more amenable
host such as E.coli, yeast or mammalian cells. It is not
so easy to identify all protective antigens, clone and
express in a suitable vector, though this technique
helped to clone a gene of interest. It has its own
limitations such as in a complex protein like lipoprotein
or glycoprotein, the post-translational machinery may
not be full proof and this may hamper the antigenicity
or immunogenicity of the molecule as the translated
protein may not acquire the actual conformation of the
native protein. The current strategies of vaccine design
include primarily at preventing the pathogen invasion
and / or neutralization of the disease inducing toxins
by antibodies and fine tuning the cellular immune
responses to preferentially induce CD4+ Th1 or Th2
cytokine profile. The outcome of the progression of
disease or the elimination of pathogen is decided by
the outcome of cytokine involving Th1 and Th2
dichotomy. Also, the involvement of specialized antigen
presenting cells for the induction of helper and cytotoxic
T lymphocyte or both response by the use of
214
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
immunomodulatory molecules and new delivery
systems like liposomes, ISCOMs and microsphere
technologies has certainly improved the quality of
vaccine efficacy. Since all the above qualities lie in
peptide based vaccines this seems to be the most
logical and likely answer in the present era to
circumvent the above problems.
The current emphasis is on developing a formulation
that can activate both systemic as well as mucosal
immune responses especially where the transmission
is occurring through oral/nasal/rectal routes.
Many infectious pathogens contain certain moieties,
which are recognized by the phagocytes. This leads to
release of proinflammatory cytokines, which eventually
attract the lymphocytes at the site of infection as a part
of innate immunity. This eventually leads to decrease
in load of infection. When acquired immunity starts it is
easy to handle the pathogen subsequently.
Recently, emphasis is made on Toll-like receptors that
mediate innate immunity. The new class of adjuvants
as well as delivery vehicles has shown to negate their
action through these receptors only.
Protein Antigenicity vs Immunogenicity
Vaccination, in general, involves the use of an
immunizing agent, which is expected to elicit protection
by the formation of neutralizing antibodies against a
biologically active molecule such as bacterium or virus
Table 1. Vaccine Development And Licensure 1945-1996
Viral vaccines
Vaccine
Bacterial vaccines and globulins
Vaccine
Date
Killed
Bacterial Subunit
Japanese B
Meningococcus A
1974
Pandemic A2 influenza
Meningococcus C
1975
Adenovirus
Combined
Purified Poliovirus
A-C
1975
Purified Influenza
A-C-Y-W 135
1982
Adjuvanted Influenza
Pneumococcus
Hepatitis B
14 types
1977
Plasma-derived
23 types
1983
Recombinant
H. Influenzae
Hepatitis A
Conjugate
1989
Live
Measles
Immune Globulins
Edmonston B+
Hepatitis B
1978
Gamma Globulin
Hepatitis A
1979
More Attenuated
Mumps
Rubella
Combined live vaccines
Measles-smallpox
Mumps-rubella
Measles-mumps
Measles, mumps, rubella (MMR)
Varicella
Marek’s Disease
(Cancer of Chickens)
Indian Journal of Clinical Biochemistry, 2005
215
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
Table 2. Strategies for the development of
Non-living Vaccines
*
Whole chemically inactivated organisms
*
Toxins-chemically inactivated
*
Toxins-genetically inactivated
*
Excreted antigens
*
Capsular polysaccharides
*
Protein-conjugated polysaccharides
*
Subunits of organisms including OMPs
and envelope antigens
*
Subunit antigens produced in recombinant
organisms
Table 3. Vaccines to be licensed by 2005
Hexavalent combination for infants
(Phase-III clinical trials)
H.Influenza (attenuated)
Lyme disease
MMR-varicella
Meningococcal A/C conjugates
Pneumococcal multiple serotype conjugates
Rotavirus (oral)
Leprosy
Table 4. Principal vaccine targets beyond 2005
*
Synthetic peptides with B and T epitopes
Chlamydia pneumonia
Human papilloma
*
Pseudoparticles produced in vitro lacking
replicative capacity
CMV
Malaria
*
Anti-idiotypic antibodies
*
Naked DNA
or toxin. The exact mechanism of this protection is not
clearly known, it is not certain whether all the antibodies
elicited by the vaccine participate in the neutralization
process. Moreover, these questions are not amicable
to experimental elucidation due to huge size and
complexity of the immunizing molecule. Infact, only a
small percentage of the antibodies participate in the
neutralization, whereas other determinants may
frequently induce the opposite effect resulting in
immunosuppression, which could be detrimental to
the host defense mechanism. If we are able to find
means to elicit only neutralizing antibodies, then
immunization would be more effective and protective.
The portion of the protein bound by specific antibody
molecule is antigenic and recognized by that particular
antibody. One viewpoint is that certain parts of protein
are inherently antigenic and that this property would
be intrinsic to the nature of the molecule and
independent of the host to be immunized. On the basis
of this concept attempts have been made to define the
properties of certain protein sub-structures, which
might make them inherently antigenic. This is possible,
provided the actual epitopes recognized by B and T
lymphocytes are mapped or predicted. Several tumor
associated antigens (TAA) in melanoma and other
cancers have been shown to be important in
understanding tumor immunology (6). Most of the
melanoma antigens have been identified by screening
cDNA libraries (7) or identification of TAA involves the
testing of known proteins for recognition of CTL property
(8) or directly isolating and sequencing peptides eluted
from the tumor cells (9). Most recently computer
programs have been used to identify the peptide
sequences of known proteins based on their binding
affinity for selected HLA molecules (10). Three types of
antigenic sites have been determined: sequential,
Indian Journal of Clinical Biochemistry, 2005
Dengue
Meningococcal B
EBV
Otitis
Group B Streptococcal
Respiratory syncytial
Helicobacter
Tuberculosis
Herpes Simplex
Zoster
HIV
Anthrax
Cancer
Plague
continuous and discontinuous. In sequential
determinants the antibodies recognize the linear
sequence of aminoacids. A continuous antigenic site
is a conformationally distinct portion of the protein that
is comprised of aminoacids in continuous peptide
bond linkage. A discontinuous site is one, which is
conformationally distinct and is made of aminoacids
not by peptide linkage but due to secondary or tertiary
folding of the protein (11). The strength (affinity/avidity)
of an antigen antibody complex is also governed by
the molecule stereochemistry of its aminoacids. An
effective immunogen will have two spatially distinct
sites for B cell as well as T cell interactions. There are
many approaches that have been developed from time
to time with high fidelity of success to map or identify
the antigenic sites on the protein molecules. During
normal course of the antibody production, there are
certain regions on a given protein molecule, to, which
antibodies are predominantly generated called as
immunodominant regions (12). With the identification
of these immunodominant epitopes in large number
of proteins interesting applications have been seen in
diagnosis of the disease (13) or as T cell help to the
hapten. Sometimes a single amino acid substitution
in an immunodominant region refocuses the immune
response and makes it a weak immunogen, thus
proving the role of these immunodominant regions in
vaccine design (14). A dominant region of a pathogen
protein which has homology with host proteins may
216
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
lead to autoimmune diseases through breaking of the
tolerance to the self determinants (13). In contrary, an
immune recessive site is a site, which is less exposed,
extremely buried. These regions may provoke
induction of suppressor T cells that act to suppress
the production of mature B cells. Immunosilent regions
are the regions, which are immunologically silent, and
they do not provoke any antibody response. In an
exceptional study, it is amazing to understand that
cryptic sequences (normally they do not provoke
immune response in the native antigen) have shown
to be protective epitopes (unpublished data). However,
other regions are also accessible to the immune
response but are called minor determinants of the
protein. For generating an effective immune response
for a peptide based vaccine, the need to understand
the knowledge regarding immunodominance-a
property where strong humoral response is mounted
with the co- operation of the T cell, is needed (15,16).
From the above studies, it is very clear that the
knowledge of immunodominance, immunorecessive,
immunosilent regions and cryptic sequences of a
protein play a key role in generating overall immune
response during the design of peptide vaccines.
Synthetic Peptide Vaccines
The basis for synthetic peptide vaccines was laid by
the pioneering work of Anderer who showed that short
fragments of a protein from tobacco mosaic virus could
inhibit the precipitation of the virus by antiserum. Also,
when a hexapeptide from the fragment is coupled with
a carrier it induced specific virus precipitating and
neutralizing antibodies (17). Further work by Arnon et
al. extended this concept to show that chemically
synthesized peptides could also induce antibodies that
specifically recognize the intact virus particle from
whose coat-protein, the amino acid sequence was
derived and generated antibodies. With the advent of
gene cloning and nucleic acid sequencing techniques,
a large number of aminoacid sequences of biologically
important proteins are now available. This is
undoubtedly responsible for the greatly increased
activity in the search for synthetic peptide vaccine by
many laboratories. The first step in developing a
synthetic peptide vaccine is to identify the relevant
antigen(s) and determine its amino acid sequence.
This is now mostly achieved by deducing from the
nucleic acid sequence of the gene coding the protein.
The next step is to identify the relevant antigenic
determinant. This is perhaps the most difficult part
and may be achieved by using the following
parameters:
1.
Chemical and enzymatic cleavage of purified
proteins and subsequent analysis of their
immunological properties.
2.
The use of monoclonal antibodies to identify and
Indian Journal of Clinical Biochemistry, 2005
select the smallest component of the antigen still
capable of specific binding activity.
3.
Predictions based on regions of hypervariability
when amino acid sequences of a number of
variants are available.
4.
Predictions of secondary and tertiary structures
by computer chemistry, which indicate regions of
hydrophilicity, accessibility and mobility based on
the state of lowest free energy.
5.
Random synthesis of overlapping peptides.
6.
Regions around disulphide bridges that locks the
native conformation.
7.
The use of hydrophilicity parameters of individual
amino acids derived from the HPLC (high
performance liquid chromatography) retention
times to predict surface residues on the protein
antigens. (18).
8.
Isolation of the peptide sequence that is released
during proteolysis of the antigen monoclonal
antibody complex (19).
9.
Developing a peptide microarray for the antigen
of interest to delineate the helper, cytotoxic and
humoral sites.
Concept of Synthetic Vaccines
The concept of synthetic vaccine must not only include
the synthesis of immunogenic epitopes eliciting a
protective antibody response, but also have the
epitopes for sensitizing the specific T-helper / T-cytotoxic
cells for long lasting immunity. This way, it can eliminate
the intracellular pathogens through various effector
mechanisms (20).
Thus for a peptide vaccine to be effective in a broader
population of diverse HLA alleles, the following points
should be met:
1.
The immune response should be directed
against the determinant(s) that are invariant within
the population.
2.
The immune response should be elicited in
almost all the individuals of an outbred population
i.e. there should be no genetic restriction at the
host level against the synthetic vaccine.
3.
Both the T and B cells should cooperate with each
other in the immune response in order to produce
long lasting immunity and memory.
4.
Cross-reactive antigens should be eliminated in
order to obviate any undesirable immune
response.
217
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
Advantages of Synthetic Peptide Vaccines over Other
Vaccines
The main advantages of using synthetic vaccines may
be summarized as follows:
1.
They can be produced in large quantity.
2.
The peptide vaccines are stable at room
temperature
3.
The stability of the peptide vaccine makes it
suitable for applications in delayed release
vehicles and thus the slow release profile mimics
the booster response of vaccine.
4.
It is possible to attach several peptides,
representing the relevant portions of different
pathogens to the same carrier molecule
effectively giving a multivalent vaccine.
5.
Their use will eliminate immunization against
many irrelevant antigenic determinants of the virus
or irrelevant proteins that contaminate the viral
preparation.
6.
Many vaccines need an adjuvant to enhance the
immune response. In synthetic vaccine, it is
always highly desirable to introduce certain
groups that augment antigenicity. Thus, the
synthetic vaccine should contain built-in
adjuvanticity and may prove to be less hazardous
and of better quality for humans.
7.
The peptide vaccine is defined in chemical terms
and is free from infectious material/any
contamination.
8.
Unlike the conventional vaccine, synthetic vaccine
need not to be propagated in the unnatural host
hence, no fear of autoimmunity / cancer.
Antibodies against the synthetic peptide immunogens
may provide reagents for passive immunity, antitoxin
therapy, targeted immunotherapy of neoplasia,
radioimaging of tumors and finally for use in
immunodiagnostics (21).
Synthetic Vaccines can be Divided into Two
Categories
1.
Chemically synthesized or peptide vaccines
2.
Recombinant vaccines
Peptide Design
The synthesis of peptides corresponding in sequence
to the primary structure of antigenic regions of a
pathogen represents another way of developing noninfectious surrogate vaccines. The potential
effectiveness of a synthetic peptide vaccine is usually
reflected in its ability to elicit the formation of neutralizing
Indian Journal of Clinical Biochemistry, 2005
antibodies and/or immunological memory. Synthetic
antigens might be of considerable importance in the
future development of vaccines (22). They may be
converted into potent immunogens by being coupled
with proteins that activate the immune system and invite
the participation of T-helper antigenic sites. The
development of synthetic molecules along with the Bcell epitopes will allow the design and development of
inexpensive, efficient vaccines. They should avoid
possibly deleterious sites, such as suppressor T-cell
epitopes or sites involved in tolerance (23).
The following guidelines may help in making vaccines
better.
1.
Identification of precise epitopes within the
predicted sequence by synthesizing overlapping
peptides with single amino-acid deletions from
the N-or C-terminus of the predicted sequence
which is finally recognized by T-cells in association
with many MHC class II / class I molecules.
2.
Construct multiple antigen system.
3.
Inclusion of a universal T-helper epitope into the
vaccine since the immune response to a given
epitope is normally under genetic restriction.
4.
Mimicking of the conformation of the native
epitope by disulphide bonding to form a circle
that enhances the antigenicity of the synthetic
oligopeptides.
5.
Linking of hydrophilic epitopes between
hydrophobic segments to provide correct folding
to stimulate immune responses against different
epitopes in a single synthetic chain.
6.
Introduce some motif that allow polymerization/
cross-linking of each epitope.
7.
Palmitoylation of peptides leads to CTL response.
Structural Factors in Peptide Vaccine Design
In order to be effective, a synthetic peptide vaccine must
possess a high level of immunogenicity and induce
antibodies that cross-react extensively with the
pathogen. Developing peptides suitable for vaccination
is a far more difficult task than selecting peptides able
to induce antibodies that simply cross-react with the
cognate protein. At times, certain structural
modifications have shown a marked increase in the
antigenicity/immunogenicity of synthetic vaccines. Little
evidence support the role of carbohydrates as
immunogens in protection or prevention of a disease
but majority of the studies show that they have a very
little role to play in elimination of the pathogen. The
majority of the studies involving bacterial pathogens
show that anti-carbohydrate antibodies have a negative
effect either in enhancing the multiplication of the
218
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
pathogen or are involved in pathogenesis of a disease.
The role of carbohydrates observed in majority of
diseases is in receptor recognition and also the site of
protein modification or protection of the antigen from
degradation by burying some potential tryptic and
chymotryptic sites (24). Addition of carbohydrate
residues also helps in the modulation of antigenicity
by stabilizing the three-dimensional structure of the
molecule. Masking and unmasking of the protein is
another important function of the carbohydrate. This
may lead to exposure of the antibody binding sites in
the areas previously buried in the native molecule.
Thus, efficacy may be greatly enhanced by altering the
position and number of carbohydrate residues in a
synthetic protein vaccine. Local secondary structures
can also be dramatically altered by changes in the
sequence. Substitution of a polar residue for a
hydrophobic residue may lead to the exposure of buried
residues e.g. foot and mouth disease peptide VPI (25).
Further in some cases disulphide bridges have been
shown to be critical for the maintenance of the native
antigenic and/ or immunogenic activity. In the hepatitis
B surface antigen peptide, the presence of an intrachain disulphide bond (between 124 and 137) makes
this cyclic peptide exceptionally immunogenic (26).
Acylation of the N-terminal of synthetic peptides by long
chain fatty acids has also been shown to increase the
immunogenicity. Myristylated, as opposed to
unmyristylated pre-S peptide of the hepatitis B envelope
protein has been shown to be immunogenic in sub
human primates (27). Unless the protective
determinants are identified and isolated, it is easy to
make tailor made sequences retaining their
immunogenic properties, though it would not be
possible to produce a highly specific vaccine free from
infectious material.
Mapping of T-and B-Cell Antigenic Determinants
Successful induction of immunity to most antigens
requires the recognition by T and B cell of every different
epitope. T cells are important regulators of immune
responses and it has become increasingly clear that
the class of T cell preferentially activated in an immune
response is of pivotal importance for its strength and
for the generation of effector mechanism. Hence, the
ability to predict regions of protein sequence most likely
to elicit T cell immunity would be of potential use in
vaccine development.
A computer algorithm designed to predict antigenic
regions in a given protein does so by: 1.
The use of hydrophilicity parameters of individual
amino acids derived from the HPLC retention
times to predict surface residues on the protein
antigens (18).
2.
The use of hydrophilicity-recognition profiles of
proteins.
Indian Journal of Clinical Biochemistry, 2005
3.
Predicting local secondary structure, i.e. α-helix,
β-pleated or random structure.
4.
Looking for an amphipathic structure, i.e. a
structure in which the hydrophobic residues tend
to occur on opposite faces. These two sides may
serve to interact with the MHC molecule on the
antigen-presenting cell and with the T cell
receptor (28).
5.
The isolation of the peptide sequence that is
released during the proteolysis of the antigenMoAb (monoclonal antibody) complex (19).
6.
Constructing peptide sequences that are comers
of the folded polypeptide chain.
7.
Sequence accessibility, antigenic index and
hydrophilicity parameters.
Role of MHC in Peptide Vaccine Design
The ability of an individual to respond to a given antigen
is controlled by Immune response (Ir) genes. In the
epitope or peptide based vaccines, the immune
response is restricted since the peptide binds to a
restricted MHC molecule. This allele specific nature of
peptide binding to MHC molecules indicates that single
peptide vaccine will be ineffective except in the most
limited homogeneous population. In general, multiple
peptides or proteins yielding peptide fragments will
be necessary to ensure that all members of a
heterogeneous population possessing diverse MHC
alleles can capture and present to their T cells at least
one effective antigen. Normally the size of the peptide
recognized by class II molecule are usually between
10-20 amino acids in length while the size for class I
molecule is 9-10 amino acids in length. Peptide class
II interaction has been analyzed in detail both at the
structural and functional level and peptide-binding
motifs have been proposed for various mouse/human
class II specificity (29). In some cases, the peptide
produced from the proteins of an infective agent will
not contain optimal motifs for binding to prevalent MHC
molecules in the populations. Predictions based on
these motifs appear to be less accurate for class I
molecules. This is because the peptide binding groove
for class II molecule are open on both the sides thereby
allowing different motifs to bind to single MHC
molecule (30). This methodology helped to engineer
non-natural T helper epitope by modulating either MHC
binding affinity or alteration of TCR (T cell Receptor)
contact residue or both. One such epitope identified
for class II binding is PADRE peptide (31). This
methodology helped to engineer non-natural T helper
epitope by modulating either MHC binding affinity or
alteration of TCR (T cell receptor) contact residue or
both. In such cases, the introduction of suitable motif
residues or the elimination of dominant negative
residues (32) can make some improvement in the
219
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
vaccine material. Under proper circumstance, such
peptides will stimulate T cells and still be able to
recognize the native peptide bound to the same MHC
molecule. This is because primed T cells require lower
levels of TCR ligand for stimulation, for the lower efficacy
of the natural peptide in forming the complexes with
MHC molecule will still permit activation of the T cells
previously primed by the modified peptide. It is also
possible to identify the key residues controlling the T
cell specificity (epitope residues) rather than MHC
molecule binding and produce the vaccine material
with multiple substitution at such position to preclude
escape from immune destruction due to pathogen
sequence variation at these sites (33). With reference
to class I pathway, the antigen/peptide should have
the access to the cytoplasmic delivery. This can be
accomplished either by using live vehicles or liposomal
delivery. Another important point is, it is crucial to ensure
that load of the distinct antigens in a combined vaccine
does not exceed the capacity of the presentation system
because help for B cell antibody production involves
recognition of peptide-MHC class II complex on the B
cell. Sequestering the circulating antibodies can
minimize another level of peptide competition.
Immunogenicity of Peptides
Despite considerable research over many years the
only adjuvant currently approved as gold standard for
use with vaccines is alum but comparative studies
show that it is a relatively weak adjuvant for antibody
induction and a poor adjuvant for the induction of cellmediated immunity. There is an urgent need to
supplement this adjuvant with improved delivery
systems, which are potent and safe and can be used
with new generation vaccines. In order to increase the
immunogenicity of peptide vaccine two important
criteria should be satisfied. Firstly, efficient presentation
of the processed antigen to the T-cell receptor.
Secondly, immune response to be uniformly generated
in outbred population. In an attempt to achieve the
above goal, we have used two approaches.
Simultaneously, present the antigen in a particulate
form so that antigen can be released slowly into
circulation in depot formulation more so with liposomes
or ISCOMs (Immunostimulating Complex’s) or
microspheres (34) or in continuous and pulsatile form
(35). The influence of immunoadjuvants on the
qualitative aspect of immune response should not be
ignored and hence, we have used panel of
immunoadjuvants that are non-toxic, permissible and
water-soluble. Adjuvants include a polymer of tuftsin
(36), bio-active fragment of IL-1 α (37), MDP analog
such
as
murabutide
(38)
and
casein
immunomodulatory sequence (39). A combination of
adjuvants with modified delivery vehicles undoubtedly
increased the immunogenicity of otherwise nonimmunogenic peptide fragments of CS protein of P.
vivax, RESA antigen of P. falciparum (40,41) and
Indian Journal of Clinical Biochemistry, 2005
envelope & core peptide sequences of HIV-I. Such an
approach had generated high titer and high affinity
antibodies. The quality of the generated isotype is
polarized towards IgG 2a/2b, which are known to be
cytophilic in nature, activates complement, enhance
phagocytosis and clear the pathogen through ADCC
mechanism. Most importantly the generated antibodies
inhibited the growth of the relevant pathogen in-vitro.
The influence of such an approach had also contributed
to cell-mediated immunity through activation/
expansion of splenic lymphocytes and generated
cytokines, which are predominately of IL-2 and IFN-γ
(CD4+ TH1)(42,43). As most of the studies were done
in inbred mice with different genetic background as
well as in outbred strains, the outcome of the study
undoubtedly proves that there is no MHC linked
immune response with any of the above strains.
One of the rationales for designing engineered
vaccines is based on putting together individual defined
epitopes for eg. as in HIV one can select epitopes that
induce neutralizing antibodies, cytotoxic and helper T
cells that might be protective thereby avoiding epitopes
that induce enhancing antibodies, autoimmune
responses or suppressor cells. One can combine the
epitopes in various ways to make them potentially
active. This can be achieved by producing multivalent
constructs (44) or combining some neutralizing
sequences arising from different clades of pathogens
(45,46) or instead improvise on these epitopes by
tinkering with the internal structure of the antigenic
determinant or antigenic site. It is always mandatory
that for generating neutralizing antibodies that crossreact with native protein, the selected peptide should
assume the necessary requisite conformation adopted
by the native protein. In such circumstances, the
importance of physical parameters like free energy of
conformation plays a major role in critical binding of
antigen antibody complex. The hypothesis is that if
MHC molecules can combine to host of peptides and
only a few specific side chains are necessary for
positive interaction, then negative or adverse
interactions at nonessential positions should playa
role in determining the specificity of peptide MHC
binding. Therefore by identifying the different residues
in a peptide may suggest ways to improve the antigenic
activity and the nonessential residues might be
replaced to enhance the function (47). In another study
as in the case of VP1 protein of foot and mouth disease
virus it is observed that the most variable regions of
VP1 would be those subject to immunological
pressure for mutation, which would be the site of
greatest antigenicity. The obvious property associated
with genetic polymorphism of class I and class II
molecules determine the specificity and affinity of
peptide binding is in T cell recognition. In other words,
individuals with different haplotypes will vary in CMI
response to the same antigen. It is therefore important
220
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
to identify the peptides recognized by T cells for efficient
protection against the disease. In theory all these
studies suggest that it is possible to map the specificity
of CTL clones by using a panel of recombinants
expressing the overlapping peptides to create targets
but in practice it is however more common to use
synthetic peptides in conjunction to computer
predictions.
In one of the studies in cancer it was observed that
identification of peptide sequences recognizing CTL
has led to direct induction of CTL responses in-vivo
(48). To stimulate the CD4+ T cells that respond to
peptides presented by class II molecule, proteins must
be delivered efficiently to the endosomal-processing
compartment. Thus the delivery vehicle is important in
maximizing such delivery. Also particulate antigen and
delivery in a concentrated form may help class II
pathway. Another way is to use ligand conjugation so
that cellular receptors are used to enhance endocytic
uptake of the antigen. Another way is to regulate the
stage in the endosomal pathway when the antigen is
available during processing. In one of the study it was
observed that a fusion peptide with an endoplasmic
reticulum-signal sequence at the amino terminus was
more effective in generation of CTL response than the
peptide itself (49). Numerous reports are available in
the literature regarding peptide vaccination for cancer.
It was demonstrated that there is tumor regression by
immunisation with MAGE-3 derived peptide even in
the absence of any adjuvant (50). Furthermore there is
generation of CTL specific responses for gp100 derived
(51) peptides immunised with Incomplete Freunds
adjuvant. Many peptide vaccines are being studied
currently e.g. peptides derived from MART-I, tyrosinase,
gpl00, MAGE-3 (52,53), prostate specific antigen (54).
Several strategies for the modification of these peptides
such as lipidification or changing anchor residues that
binds to HLA motif are also being attempted
(Rosenberg et al. 1998) to produce an efficacious
vaccine against all types of cancers. Many studies have
been coming up for a better design of peptide vaccine
by exploring the immunological specificity using
synthetic peptide combinatorial libraries (55). The use
of this approach has four major effects: first, the
definition of high affinity ligands for both T cells and
antibodies; second, the application of alternative
means for identifying immunologically relevant
peptides for use as potential preventive and therapeutic
vaccines; third, a new appreciation of the requirement
for TCR interactions with peptide -MHC complexes in
immunogenicity; fourth, the establishment of new
principles regarding the level of cross reactivity in
immunological recognition. Though peptide based
vaccines have enormous advantages, it has few
disadvantages:
1.
Synthetic peptides are poor immunogens.
Indian Journal of Clinical Biochemistry, 2005
2.
They are mono specific in the induction of immune
response.
3.
Generated immune response is not uniform in
outbred populations.
4.
As the length of the peptide fragment is short it
may contain insufficient information to fold into
the correct shape necessary to mimic
conformationally dependent epitope.
Plausible Ways of Overcoming the Disadvantages
The above drawbacks can be circumvented by use of
adjuvant or controlled delivery vehicles i.e. ISCOMs,
Liposomes or Microspheres. Chemical conjugates
with antigen derived viral or bacterial proteins controlled
polymerization of some of the epitopes and lipopeptide
conjugation or using MAP (Multiple peptide antigens)
comprising of T and B cell epitopes coming from same
antigen or from different antigens also provide an
effective method of synthesis of many epitopes in a
well defined orientation using a branched oligolysine
matrix. All these approaches produce a long lasting B
cell, T helper and CTL response provided there is no
epitopic competition in between multiple antigens and
thus leading to suppression of antibody production to
otherwise dominant epitopes. Strategies to enhance
immunogenicity of these candidate vaccines are
therefore critical.
Several types of immunoenhancers are under
investigation. They work in a variety of ways by changing
the conformation of the antigen thereby enhancing the
antigen presentation, by preventing the proteolytic
destruction of the antigen in the stomach thus allowing
it to pass into the intestines intact for presentation to
gut associated lymphoid tissues or by targeting the
antigen directly to M cells of the gut to induce mucosal
immune response or by the induction of various
immunomodulatory cytokines such as GMCSF, IL-12,
TNF-α that act directly on the thymus/derived helper T
cells to stimulate specific arm of immune responses.
The exact molecular or cellular mechanism required
for the generation of an effective immune response invivo depends on the co-injection with adjuvant, which
need proper understanding (56). Therefore, they are
still surrounded by obscurity and called as
“immunologists dirty little secret” (57). Therefore for
the formulation of a highly effective subunit vaccine,
the inclusion of strong immunoadjuvants and / or
proper delivery vehicle has become essential to elicit
optimal immune response in the host.
Adjuvants and Delivery Systems
The poor immunogenicity of peptide vaccines and
thus, their ineffectiveness in soluble form to generate
an effective immune response necessitate the
following guide lines:
221
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
1.
Increase the antigen absorption
2.
Prevent its degradation and
3.
Show the outcome of immunization to a desired
goal (protective response against infectious
diseases vs tolerance, B vs T cell response;
mucosal vs systemic).
Adjuvants are defined as a group of structurally
heterogeneous compounds, used to evoke or increase
an immune response to an antigen (58). The concept
of an adjuvant, an immunity stimulating substance,
enhances the specific immune response, both
humoral and cell mediated, to a protein antigen (59).
Classically recognized examples include oil
emulsions, saponins, aluminium or calcium salts, nonionic block polymer surfactants, derivatives of
lipopolysaccharides, MDP, mycobacteria and others
(like Vitamin E and Fluoride). Theoretically each
molecule or substance is able to favor or amplify a
particular situation in the cascade of immunological
events, ultimately leading to a better immunological
response is defined as an adjuvant (60). Adjuvants or
delivery systems modulate the immunogenicity of
antigens either by simply prolonging the half-life in the
recipient or through activation or combination of effector
mechanisms. This is achieved by acting as a depot for
slow release of antigens or preserve the
conformational integrity of the antigen for better antigen
presentation or secrete immunomodulatory cytokines
or induce helper or cytotoxic response or by targeting
the antigen to cell surface receptors for better
opsonization. They are known to modulate antibody
avidity, specificity, isotype or subclass distribution. They
enhance the immune responses in immunologically
immature or senescent individuals. At the start of this
century, there was almost no adjuvant research or
report other than aluminium salts. Although aluminium
salts are the only adjuvant registered for human use,
numerous immunomodulators have been developed
during the past decade to allow for both an increase in
immunogenicity of peptide antigens, but also to allow
for delivery to new sites such as mucosal area.
Adjuvants come in many different forms and are
generally considered both for delivery of antigen(s) and
as immunostimulant that has a direct effect in the
immune system. Delivery systems for vaccines have
been designed to this date either to improve parenteral
delivery or to allow for a new approach in vaccinology
such as in mucosal delivery (61). Although the immune
response obtained after parenteral or mucosal
administration differ, the various types of delivery
systems that are being developed are to induce both
mucosal & systemic immune response. The currently
available adjuvants and delivery vehicles can be
classified as particulate, nonparticulate and others.
Particulate adjuvants include the aluminium salts,
surface-active agents, slow releasing vehicles like FCA,
Indian Journal of Clinical Biochemistry, 2005
liposomes, Novasomes, IRIV’s, ISCOMs (62) and
microspheres (63). Nonparticulate includes non-ionic
block copolymers, glycopeptides and lipopeptides, and
peptides of microbial origin. Other adjuvants being
used are proteosomes, cytokines, Trat, polytuftsin,
QS21, MF59, Montanide, mucosal adjuvants like
cholera toxin-B, CpG DNA, lectins, LT (R192G), IgA and
cochleates (64). The induction of immune response
at a desired site can be accentuated with the use of
bacterial or live vectors (65), which contain the genes
from unrelated microbial species that encode important
virulence factors and antigens. These vectors have
been used especially in mucosal immunizations i.e.
Salmonella, E.coli, mycobacterium, lactobacilli, polio,
adeno, rhino, meningo, influenza, vaccinia and canary
pox virus have been used in various animal models
with only salmonella typhi and adeno virus used in
human system (66). As the parenteral route(s) of
immunization generates systemic immune response
only hence, we in our laboratory are currently
emphasizing the relevance of both systemic (IgG) as
well as mucosal immunity (secretory IgA). We are
targeting the antigens to the M cells of Peyer’s patches
(GALT / NALT) after entrapping the antigen in
microspheres or by using a ligand having specificity
for M cell in diseases like HIV (67) and Plague
(unpublished data).
By use of delivery systems like ISCOMs in which Quil A
is combined with cholesterol or other lipids like
phosphatidylcholine to form honey comb matrix of
micelle and thus the Ag attaching itself by hydrophobic
interactions. By these interactions multiple sites of the
Ag are presented to the antigen presenting cells and
thus it enhances the immunogenicity of the antigen
(68).
The use of liposomes, which are bilayered
phospholipid vesicles, are non toxic and safe for
human use. They have been viewed as potential
replacement for aluminium based vaccines due to their
flexibility biocompatibility and biodegradability. They
present no toxicity in human and provide efficiency in
many experimental protocols.
The use of microspheres provides a delivery vehicle
both for mucosal as well as systemic immunization
(69). They are designed to slowly release the antigen
at various time points in the tissues, various polymers
have been used for preparation of such microspheres
with the most-widely used being Poly lactic coglycolide. They also come under the category of
nontoxic, biocompatible and biodegradable adjuvants
(70).
Fluoride, the agent responsible for reduction of dental
carries is shown to be a potent adjuvant when given
intra-gastrically to rats. Ingestion of fluoride can
modulate the immune response to orally and
222
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
parenterally administered antigens have shown to
stimulate the proliferation of intestinal lymphoid tissue
(71). Vitamin E and Vitamin A are antioxidant vitamins
and are proved to be good immunopotentiators
because they protect the sensitive rapidly proliferating
cells of the immune system from oxidation damage
and increase cell interaction by membrane alteration.
The adjuvant emulsion amplifies local inflammatory
reactions, attracting polymorphonucleocytes, dendritic
cells, macrophages and lymphocytes to the site of
injection, allowing optimal interaction between antigen,
antigen processing cells and the vitamin. The vitamin
acts as a physical constituent of the emulsion as well
as a potent immunoenhancer (72).
Other Types of Vaccines
Poly topic vaccines
In its present and simplest form, the new science of
vaccinology might be considered to be the science of
epitopes. These are immunological determinants of
antigens whose presentation, either in native or
processed form to the B or T cell receptor in live or
non-living forms, induces humoral and/ or cellular
immune responses and finally generates protection
against infection and disease for a sufficient period of
time. The administration in single vaccine of a highly
complex combination of appropriately selected
epitopes permits the prevention of many different
diseases in a practical way with single preparation.
These are referred to as poly topic vaccines (73). In
seeking individual epitopes, the focus has been on
the continuous or sequential epitopes that lie within
the confine of a short amino acid sequence, which can
be synthesized. Discontinuous epitopes consist of
conformational contributions by several different
segments of folded chains and are difficult to
synthesize. However, they may be approached through
the synthesis of covalent peptides that in their
conformations mimic the three-dimensional surface
of the antigenic site as well as through the synthesis
of anti-idiotypic antibodies. Sequential epitopes
normally form part of the corners of the folded
polypeptide chains.
At least four assumptions underpin the current
research endeavors into new and improved molecular
vaccines:
1.
A subset of epitopes of the pathogen from
perhaps several different antigenic molecules is
sufficient for induction of host-protective immunity
in the genetically diverse host population.
2.
Immune effector mechanisms will be identified
through basic research that is necessary or
sufficient for the expression of resistance.
3.
New,
potent,
acceptable
and
selective
Indian Journal of Clinical Biochemistry, 2005
immunostimulating agents (adjuvants) should be
made available easily with low cost.
4.
The safety of the vaccine can be assured by
exclusion of the epitopes and contaminants,
which lead to undesirable side effects whether
they are immunogenic or inflammatory.
Idiotypic Vaccines
Antigenic determinants on antibodies are invariably
immunogenic in other species since B- and T-cells
are linked mutually through idiotypic complementarity
(74). The antigen-binding site is called the paratope
and the antigenic structure associated with the variable
region of antibody is called the idiotype. Each idiotype
is composed of a set of distinct antigenic structure
called idiotopes. Antigen-binding and anti-idiotypic
antibodies belong to the same family. This implies
that each antibody molecule can bind both an epitope
on an antigenic molecule and an idiotope. The latter
appears as the internal image of the foreign epitope.
This formed the basis for using internal image
determinants as vaccines for infectious disease.
Based on the ability of the anti-idiotypes to mimic
foreign antigens, these have found use as alternatives
to conventional vaccines in inducing anti-parasitic, antiviral, anti-bacterial immunity (75). They have been
particularly effective in the following case:
1.
When the protective antigen of the infectious agent
is a polysaccharide or the carbohydrate moiety of
a glycoprotein.
2.
When the microbes show antigenic variation such
as Influenza virus, Human Immunodeficiency
virus (HIV) or Trypanosoma.
3.
By producing an idiotope, which is capable of
preventing the binding of the HIV to its receptor of
CD4+(or T helper) cells.
4.
To possibly provide a mechanism to combat
cancer by inducing a tumoricidal immune
response.
Dendritic cells (DC’s) in vaccines
A number of studies show the successful use of DC’s
for inducing antitumor immune responses in both
animals and patients (76). DC’s are known to be potent
antigen presenting cells and they initiate antigen
specific immune responses (77). In addition to this
they express high levels of MHC class I and II as well
as co-stimulatory molecules essential in antigen
presentation. They have the ability to cross present the
phagocytized dead antigens to the T cells. It was found
that peptide pulsed DC is superior to injection of peptide
in adjuvant in inducing potent CTL responses (78). A
possible disadvantage of this method is the short half
life (2-10 hrs) of most MHC restricted epitopes, which
223
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
creates the requirement for several injections of
peptide pulsed DC to achieve effective immune
response (79), Thus, development of different methods
of loading antigens allowing DC to utilize their own
intracellular pathways is highly desirable.
Edible Vaccines
Plants can be made to synthesize immunogenic
proteins and by eating these transgenic plants vaccine
antigens can be expressed for eliciting mucosal and
systemic immune response. Thus plants can be
manipulated to produce bio-medically important
substances. One of the limitations observed is,
expressing the desired antigen(s) in leaves of plants
may provide toxic effect, as it contains high levels of
toxic alkaloids. Hence, the approach has been shifted
either in tubers or fruits or seeds of plants. Though
such an approach yielded encouraging results, but
there is concern regarding such vaccine in humans
being less immunogenic (80).
Combination Vaccines
Breakthrough in molecular biology, biochemistry,
related fields have resulted in the development of many
new vaccines as well as in the improvement of several
existing ones. The successful development of
combinational vaccines is a major way to reduce the
number of vaccine administrations, thereby assuring
improved compliance with immunization schedules. A
combinational vaccine is a mixture of individual
vaccines before administration with the result that
multiple vaccines are administered together in a given
host. There are two types of combinational vaccines
multidisease (individual vaccines for different
diseases), multivalent (directed to different serotypes
or sero groups of the same viral or bacterial antigen).
There are three types of which two of them are
developed into combinations i.e. live and non-live
(includes inactivated, killed, subunit vaccines) but there
are not yet any examples of combination of live and
non-live. Till today there are six combination vaccines
available, they are DTPa, influenza, polio, MMR,
pneumococcal and meningococcal. An increasing
number of new combinations are being developed
(81).
DNA Vaccines
Direct inoculation of expression plasmids, which
results in the induction of long lasting immune of both
humoral and cellular responses against the expressed
antigens are DNA vaccines. Studies show that
intramuscular injection of DNA generated best
response where as inoculation of DNA coated to gold
particles using gene gun significantly lowered the
immunizing dose of DNA. Studies clearly show that
uptake of the injected DNA is an active energy
dependent process (82). The plasmid DNA can get
Indian Journal of Clinical Biochemistry, 2005
into the nuclear membrane or muscle cells and
persists as a non-replicating episomal molecule,
which explains the long-lived foreign gene expression
in case of DNA vaccines.
Heat Shock Proteins in Vaccines
An interesting approach in vaccine development is the
use of heat shock proteins -peptide complexes for
vaccination. Heat shock proteins derived from any given
cell type associate with a wide variety of peptides
generated during protein degradation (83). Vaccination
of mice and rats with HSP-peptide complexes has
showed powerful immune responses against
peptides bound to them, but not to HSP itself. More
recently it was reported that HSP-peptide complexes
can be used as prophylactic and therapeutic agent
even in diseases like prostate cancer (84) .The heat
shock proteins like Hsp 60/70 also have a receptor on
antigen presenting cells that helps in targeting to class
I or class II MHC molecules. Four classes of heat shock
proteins such as gp96/90/70/30 & calreticulin have
been used successfully to immunize against cancer
and other infectious diseases in prophylactic and
therapeutic protocols. Two recent studies reported
significant enhancement in DNA vaccine potency by
the linkage of antigenic genes to HSP genes (85,86).
The disadvantage of HSP in the clinical settings is the
requirement of generation of customized, patient
specific vaccines for cancer however, their ability to
elicit specific CTL response in mice of any haplotype
makes them very attractive vaccine therapeutics against
cancer.
Microarray
Microarray is a technique that provides a global analysis
of gene expression at the level of transcription. Genetic
and epigenetic changes underlie neoplastic
transformation, cardiovascular disease, some
psychiatric illness, and a growing list of disease
pathogenesis and therapeutic responses. The profile
of genes expressed by different cells(gene up and
down regulation under different conditions) determines
their phenotype, and thus provides insights in to the
molecular basis for health and disease. DNA
microarrays, which are also called DNA arrays or gene
chips are a tool that uses genome sequence
information to analyse the structure and function of
tens of thousands of genes at a time.
Each Microarray is made up of many bits of single
stranded DNA fragments arranged in a grid pattern on
the glass or plastic surface. When DNA or RNA is
applied to the array, any sequence in the sample that
find a match binds to a specific spot on the array. A
computer then determines the amount of sample
bound to each spot on the Microarray.
In a typical Microarray experiment, cDNA from one
224
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
sample(sample A) is labeled with red dye and cDNA
from another (sampleB) with green dye. The fluorescent
red and green cDNA samples are then applied to a
Microarray that contains DNA fragment corresponding
to thousands of genes. If a DNA sequence is present
both on the array and one or both samples, the
sequences bind, and a fluorescent signal sticks to a
specific spot on the array. The result of a gene
expression experiment are referred to as a gene
expression ‘profile’ or ‘signature’.e.g. microarrays can
be used to diagnose different cancers by comparing
the profile of a cancer cel with that of a normal cell.
Similarly, microarrays can determine which genes are
turned on during cell division by comparing the
expression profile of a cell that is in resting state to the
profile of one that is dividing (87).
diagnosis, therapy and vaccine development (87,89)
Medical Applications of Synthetic Peptides
1.
It is important to remember that there is an age
dependent increase in antibody level, which was
observed by us while studying malaria endemicity,
using repeat sequence of CS and Ring infected
erythrocytic stage antigen (RESA) peptides of P.
falciparum and P. vivax as test antigens. This
observation correlates well with parasitaemia on
the one hand and with antibody levels on the other.
However, interestingly no correlation was found
between the levels of CS antibodies and blood
stage antibodies in the same population. Thus
the response to CS peptide appears to develop
at an earlier stage than the response to blood
stage peptides, though this approach
discriminates current infection with past infection.
Protein Arrays
Protein arrays that are used to identify proteins typically
consist of many antibodies arrayed on a glass or plastic
slide. Each antibody can bind to a different target
protein. Bound proteins can be detected either by
adding a second antibody tagged with a fluorescent
molecule or by chemical labeling the proteins. Each
bound protein can therefore be detected as a signal
on the array, and the intensity of the signal roughly
represents the amount of the protein present.
Medical application of micro array technology
The most important application of microarrays is in
the study of differential gene expression in disease
and health, and in normal and abnormal physiologic
and immunologic responses. Diversion in normal
physiology is frequently accompanied by panoply of
histological and biochemical changes including in
gene expression patterns. The up-or down-regulation
of gene activity can either be the cause of
pathophysiology or the result of disease. To study the
fine changes in the expression of these thousands of
genes affected in a diseased state is almost
impossible without the help of this powerful microarray
technology. Microarrays promise to accelerate the
understanding of the host as well as the pathogen
side of the host-pathogen interaction. A large fraction
of the genome can be simultaneously interrogated,
and clustering of the data may identify groups of genes
that influence activation or repression of key regulatory
pathways. The opportunity to compare the expression
of thousands of genes in varied pathophysiological
conditions allows the identification of virulence factors
that can aid better and inform vaccine design (87,88)
In conclusion, in the context of vaccine research, the
power of microarrays combined with transcript profiling
and cluster analysis is such that it allows the subclassification of disease types and identification of
molecular targets, which may have relevance for
Indian Journal of Clinical Biochemistry, 2005
Use of synthetic peptides in serological assays:
Synthetic peptide technology permits mass
production of peptides for specific proteins,
thereby adding new information regarding the host
immune response during natural infection, age
dependent immunity in relation to intensity or
duration of exposure to a given pathogen. In fact,
the synthetic peptides have largely replaced
conventional antigens in the detection of
antibodies in the sera. They are also preferred for
raising antibodies to detect the parent antigen,
thereby increasing the mono specificity.
2.
The synthetic peptide vaccines have been used
towards the development of diagnostic assays
as in bovine tuberculosis using ESAT-6, MPB6-4
and MPB83 mycobacterial antigens expressed
at high levels in M. bovis and at low level in BCG,
pasture. Hence, bovine T cell epitopes are
identified and formulated into peptide cocktail.
(90).
3.
These peptide vaccines are used in vaccination
with heat shock proteins for tumors thus
generating anti-tumor responses. The
immunogenicity of HSP is derived from the
antigenic peptides, which they associate with
these HSP-peptide complexes and can be used
as human vaccine for cancer immunotherapy.
(91).
4.
They have a role in regulation of specific immune
responses to chemical and structural
modifications of allergens. This is achieved by
modifying B cell epitope in order to prevent IgE
binding and effector cell cross linking while
preserving T-cell epitope to retain the ability of
inducing tolerance. Thus developing novel
vaccines for the treatment of allergy (92).
225
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
5.
They can been used in the treatment of various
microbial infections by the use of diverse array of
natural, synthetic and recombinant immunomodulators and thus stimulating host defense
mechanism for prophylaxis (93).
6.
Preparation of safe malarial vaccines which are
well tolerated and gives high titer while expending
CD4+ and CD8+ lymphocyte response by using
synthetic peptides of CS and of various plasmodia
(94).
7.
8.
9.
Development of pre-erythrocytic malarial vaccine
leading to complete resistance to malarial
infection. This can be achieved by use of synthetic
peptide vaccines, multiple antigen peptides and
polyoximes from CS protein the first preerythrocytic antigen identified and present in all
malarial species (95).
Their use as vaccines against auto-immuno
diseases e.g. COP-I is a synthetic amino acid
copolymer in suppression of experimental allergic
encephalomyelitis (EAE) (96).
in one formulation to generate a response across all
the stages of the parasite. Some of the vaccine requires
the right animal model to study the protective efficacy.
Therefore it is essential to choose the right immunogen
with the right adjuvant and the best delivery vehicle to
produce an efficacious vaccine against any pathogen.
REFERENCES
1.
Jenner E (1798) An Inquiry into the Causes and
Effects of the Variolae Vaccinae. (Low, London).
2.
Salk J and Drucker J (1988) Vaccines eds SA.
Plotkin and E.A Mortimer, Ch.8 158-181
(Philadelphia: W B Saunder).
3.
Melnick JL (1988) Vaccination against
poliomyelitis: present possibilities and future
prospect. Am J Public Health. 78, 304-305.
4.
Hilleman MR (1998) Six decades of vaccine
development - a personal history. Nat. Med. Vacc.
(Suppl). 4, 5.
5.
Kumar P and Rao DN (1993) Strategies for the
development of vaccines against malaria;
Imunotechnology Biology Education. Oct-Dec,
220-225.
6.
Jason H, Jennifer AH, Bruce WL and Boris RN
(2000) Cancer vaccines: an update; In vivo. 14,
571-585.
7.
Wang XY, Kaneko Y, Repasky E and Subjeck JR
(2000) Heat shock protein and cancer
immunotherapy, Immunol. Invest. 29, 131-137.
8.
Kawakami Y, Nishimura M I, Restifo NP, Topalian
SL, Oneil BH, Shilyansky J, Yannelli JR and
Rosenberg SA (1993) T- Cell recognition of
human melanoma antigens. J. Immunother,. 14,
88-93.
9.
Storkus WJ, Zeh HJ, Maeurer MJ, Salter RD and
Lotze MT (1993) Identification of human
melanoma peptides recognised by class I
restricted tumor infiltrating T lymphocytes. J.
Immunol.. 151, 3719-3727.
Their role in generating rabies vaccines by use of
synthetic peptide technology besides employing
molecular biology tools (97).
10. An important aspect of producing large amounts
of protein or peptide is to make the product easily
purifiable. This has been done by attaching
peptides or protein to easily purified units such
as virion particles or by exporting proteins to
apoplast so that purification begins with a highly
enriched product (98).
11. Use of synthetic peptide combinational libraries
in exploring immunological specificity. (55).
12. For intervening the pregnancy at various stages
attempts have been made to develop peptide
based agents based on FSH, hCG (99), ZP3 (100)
and Sperm surface protein (101).
Future Directions for New Generation
The immediate future of the synthetic peptide
immunogen in medicine or in the veterinary field is
clear, but the results expected in the laboratory must
be translated into safe application in the field. In any
case, the ideal vaccine will most likely consist of a
cocktail of antigens or proteins. One must also
consider the dose of antigen and speed of antigen
release in the vaccine formulations. High doses of
antigen released faster may induce B& T cell tolerance.
Immune tolerance may be due to fast expansion and
subsequent elimination of specific T cell clones or
apoptosis induced by repeated stimulation of already
existing B & T cells in cell cycle (102). Protective
epitopes from various stages of parasite can be linked
Indian Journal of Clinical Biochemistry, 2005
10. Rammensee HG, Friede T and Stevanoviie S
(1995) MHC Ligands and peptide motifs: first
listing. Immunogenetics, 41, 178-228.
11. Thomas M, Shinnick, J Gregor Sutcliffe, Nicola
Green and Richard A Lerner (1983) Synthetic
peptide immunogens as vaccines. Ann. Rev.
Microbiol.. 37, 425-446.
12. Sabhnani L and Rao DN (2000) Identification of
immunodominant epitope of F1 antigen of
Yersinia pestis. FEMS Immunol Med Microbiol.
27, 155-162.
226
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
13.
Yoshida A, Nakano Y, Yamashita Y, Oho T, Ito H,
Kondo M, Ohishi M and Kooga T (2001)
Immunodominant region of Actinobacillus
actinomycetemcomitans 40 kilodalton heat shock
proteins in patients with Rheumatoid Arthritis. J.
Dent. Res. 80, 346-350.
14. Rodriguez MJ, Sarraseca J, Fominaya J ,Cortes
E, Sanz A and Casal JI (2001) Identification of an
immunodominant epitope in the C terminus of
glycoprotein 5 of porcine reproductive and
respiratory syndrome virus. J Gen Virol.. 82, 995999 .
15. Ritu G and Rao DN (1992) construction of synthetic
immunogens :Use of T- and B- cell epitopes of
CS and RESA proteins of Plasmodium
falciparum. Vaccine, 10, 761-765.
16. Sabhnani L, Manocha M, Sridevi K, Shashikiran
D, Rayanade R and Rao DN (2003) Developing
subunit immunogens using B and T cell epitopes
and their constructs derived from the F1 antigen
of Yersinis pestis using novel delivery vehicles.
FEMS Immunol and Med. Microbiol. 38, 215-229.
17. Anderer FA and Schlumberger HD (1966) Crossreactions of antisera against the terminal amino
acid and dipeptide of tobacco mosaic virus.
Biochem Biophys Acta,.115, 222-224.
18. Deber CM, Hruby VJ and Kopple KD (eds) (1985)
Peptides:
Structure
and
function.
(Rockford:PierceChemical Co.) 23p.
19. Jemmerson R and Peterson Y (1986) Mapping
epitopes on a protein antigen by the proteolysis
of antigen-antibody complex. Science, 232, 10011004.
20. Shirai M, Pendleton CD, Ahlers J, Takeshita T,
Newman M and Berzofsky J A (1994) Herper-CTL
determinant linkage required for priming of anti
HIV CD8+CTL in vivo with peptide vaccine
constructs. J. Immunol. 152, 549-556.
21.
Manzar KJ and Rao DN (1991) Antibodies to P.
falciparum Ring Infected Erythrocyte Surface
Antigen and R falciparum and P.vivax CS protein.
Med. Sci. Res. 19, 345-349 .
22. Manocha M, Sridevi K, Tomar D, Chitralekha KT
and Rao DN (2002) Synthetic peptides as
Immunoprophylaxis and immunotherapeutics.
Proc. Indian Natn Sci. Acad. B68 No.1, 29-46.
23. Frangione-Beebe M, Albrecht B, Dakappagari N,
Rose RT, Brooks CL, Schwendeman SP, Lairmore
MD and Kaumaya PT (2000) Enhanced
immunogenicity of a conformational epitope of
human T-Iymphotropic virus type 1 using a novel
Indian Journal of Clinical Biochemistry, 2005
chimeric peptide. Vaccine, 19,1068-1081.
24. Wilson ZA, Ladner RC, Skehel JJ and Wiley DC
(1983) The structure and role of the carbohydrate
moieties of influenza virus haemagglutinin.
Biochem Soc Trans. 11, 145-147.
25. Rowlands DJ, Clarke BE, Caroll AR (1983)
Chemical basis of antigenic variation in foot and
mouth disease virus. Nature, 306, 694-697.
26. Dressman GR, Sanchez Y and lonescu-Matiu
(1982) Antibody to hepatitis B surface antigen after
a single inoculation of uncoupled synthetic HbsAg
peptides. Nature, 295, 158-160.
27. Neurath AR, Seto B and Strick N (1989) Antibodies
to synthetic peptides from the pre-SI region of
hepatitis B virus envelope protein are virus
neutralizing and protective. Vaccine, 7, 234-236.
28. Margalit H, Spouge JL, Cornette JL, Cease KB,
Delisi C and Berzofsky J A (1987) Prediction of
Immunodominant helper T cell antigenic sites
from the primary sequence. J. Immunol. 138,
2213-2229.
29. Hammer J, Bono E, Gallazi F, Beunis SC, Nagy Z,
Sinigaglia F (1994) Precise predictions of Major
histocompatibility complex Class II peptide
interaction, based on peptide side scanning. J.
Exp. Med.180, 23-53.
30. Alexander J, Flixes J, Hoffman S, Franke E, Sacci
J, Appella E, Chisari FV, Guidotti LG, Chestnut
RW, Livingstone B, Sette A (1998) The optimization
of helper T lymphocytes (HTL). Function in vaccine
development. Immunological Res. 1812, 79-92.
31. Rosa DS, Tzelepis F, Cunha NG, Soares IS and
Roudrigues MM (2004) The pan HLA DR-binding
epitope
improves
adjuvant-assisted
immunization with a recombinant protein
containing a malaria vaccine candidate. Immunol.
Lett. 92, 259-268.
32. Boehncke WH, Takeshita T, Pendleton CD,
Houghten RA, Nasseri SS, Racioppi L, Berzofsky
JA and Germain RN (1993) The importance of
Dominant Negative effects of amino acid side
chain substitution in peptide-MHC molecule
interactions and T cells recognition. J.
Immunol.150, 331-341.
33. Takahashi H, Nakagawa Y, Charles PD, Houghton
RA, Yokomura K, Germain RN, and Berzofsky JA
(1992) Induction of broadly Cross-Reactive
cytotoxic T cells recognizing an HIV-1 envelope
determinant. Science, 255, 333-336.
34. Johansson M and Lovgren-Bengtsson K (1999)
Iscoms with different quillaja saponin
227
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
components differ in their immunomodulating
activities. Vaccine, 17, 2894-2900.
35. Johansen P, Estevez F, Zurbriggen R, Merkle HP,
Gluck R, Corradin G, Gander B (2000) Towards
clinical testing of a single-administration tetanus
vaccine based on PLA/ PLGA microspheres.
Vaccine, 19, 1047-1050.
45. Berzofsky JA (1991) Development of artificial
vaccines against HIV using defined epitopes.
FASEB J. 5, 2412-2418.
46. Cease KB and Berzofsky JA (1994) Towards
vaccine for AIDS: The emergence of
immunobiology-based vaccine development.
Annu. Rev. Immunol. 12, 923-989.
36. Gokulan K, Sangeeta K and Rao DN (l999)
Increase in the immunogenicity of HIV peptide
antigens by chemical linkage to polytuftsin (TK
PR40). DNA and Cell Biology, 18, 623-630.
47. Rupert J, Sidney J, Celis E, Kubo RT, Grey HM
and Sette A (1993) Prominent role of secondary
anchor residues in peptide binding to HLA-A2.1
molecule. Cell, 74,929-937.
37. Gokulan K, Sangeeta K and Rao DN (1997)
Bioactive fragments of Human IL-1â[163-171]
modulates the immune response to synthetic
peptides of HIV. Microbiol.Immunol. 41, 965-974.
48. Schulz M, Zinkernagel RM and Hengartner H
(1991) Peptide induced antiviral protection by
cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 88,
991-993.
38. Agrawal L, Haq W, Hanson CV, Duzgunes N and
Rao DN (2003) Generating neutralizing
antibodies,Th1 response and MHC nonrestricted
immunogenicity of HIV-1 env and gag peptides in
liposomes and ISCOMs with inbuilt adjuvanticity.
J.Immunebased therapies and vaccines, 1, 122.
49. Minev BR, McFarland BJ, Spiess PJ, Rosenberg
SA and Restifo NP (1994) Initial signal sequence
fused to minimal peptide elicits specific CD8+ Tcell responses and prolongs the survival of
thymoma-bearing mice. Cancer Res. 41, 55-61.
39. Thomas BE, Manocha M, Haq W, Adak T, Pillai CR
and Rao DN (2001) Modulation of humoral
response to repeat and nonrepeat sequences of
CS protein with novel adjuvant and delivery
system(s). Ann. Trop. Med. Parasitol. 95, 451-472.
40. Bhavna C, Kumar P, Haq W, Sabhnani L and Rao
DN (1998) Influence of Immunoadjuvants and
promiscuous T cell determinants on the
Immunogenicity of RESA peptide antigen of P.
falciparum. Int.J. Immunopharmac. 20, 259-273.
41. Kumar P, Biswas S and Rao DN (1998)
Potentiation of immune response against RESA
peptides of P.falciparum by incorporating universal
T-cell epitope CS T3 and immuno potentiator
(polytuftsin) and delivery through liposome.
Microbiol. Immun. 43, 561-566.
50. Marchand M, Weynants P, Rankin E, Arienti F, Belli
F, Parmiani G, Cascinelli N, Urlond A, Vanwijck R
and Humblet Y (1995) Tumor regression
responses in melanoma patients treated with a
peptide encoded by gene MAGE-3 (letter). Int. J.
Cancer, 63, 883-885.
51. Salgaller ML, Afsher A, Marincola FM, Rivoltini L,
Kawakami ‘Y, and Rosenberg SA (1995)
Recognition of multiple epitopes in the human
melanoma antigen gp 100 by peripheral blood
lymphocytes stimulated in vitro with synthetic
peptides. Cancer Res. 55, 4972-4979.
52. Jaeger E (1996) Generation of cytotoxic T-cell
responses with synthetic melanoma associated
peptides in vivo with implications for tumor
vaccines with melanoma associated antigens.
Int. J Cancer. 66, 162-169.
42. Kumar P and Rao DN (1999) Correlation of T cell
response and lymphokine profile with RESA
peptides of P.falciparum containing a universal Tcell epitope and an immunopotentiator, polytuftsin.
Microbiol. Immunol. 43, 567-576.
53. Parkhurst MR, Salgaller ML, Southwood S,
Robbins PF, Sette A, Rosenberg SA and Kawakami
Y (1996) Improved induction of melanoma reactive
CTL with peptides from the melanoma antigen
gp100 modified at HLA-A *0201-binding residues.
J. Immunol. 157, 2539-2548.
43. Thomas BE, Sridevi K, Haq W and Rao DN (2001)
Inducing cell mediated immune response
against peptide antigens of circumsporozoite
protein of P.vivax. Ann. Trop. Med. Parasitol. 95,
573-586.
54. Meidenbaur N, Harris DT, Spitler LF and Whiteside
TL (2000) Generation of PSA reactive effector cells
after vaccination with PSA-based vaccine in
patients with prostate cancer. Prostate, 43, 88100.
44. Berzofsky JA (1991) Approaches and issues in
the development of vaccines against HIV. J.
Acquired. Immune. Defic. Syndr. 4, 451-459.
55. Pinilla C, Martin R, Gran B, Appel JR, Boggiano C,
Wilson D, Bane Y and Houghten RA (1999)
Exploring Immunological specificity using
Indian Journal of Clinical Biochemistry, 2005
228
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
synthetic peptide combinatorial libraries. Curr.
Opin. Immunol. 11, 193-202.
parenteral immunization (manuscript accepted
in FEMS Immunol. and Microbiol).
56. Virgil EJ Schijns (1999) Immunological concepts
of vaccine adjuvant activity. Curr. Opinion in
Immunol.12, 456-463.
68. Stittelaar KJ, Boes J, Kersten GF, Spiekstra A,
Mulder PG, de Vries P, Roholl PJ, Dalsgaard K,
van den Dobbelsteen G, van Alphen L and
Osterhaus AD (2000) In vivo antibody response
and in vitro CTL activation induced by selected
measles candidates, prepared with purified Quil
A components. Vaccine, 18, 2482-2493.
57. Janeway CA Jr (1989) Approaching the asymptote
? Evolution and revolution in immunology. Cold
Spring Harbor Symp Quant Biol. 54, 1-13.
58.
Gupta RK, Relyveld ED, Lindblad EB, Bizzini B,
Ben-Efraim S and Gupta CK (1993) Adjuvants - a
balance between toxicity and adjuvanticity. Vaccine
11, 293-306.
59. Ramon G (1924) Sur la toxine et sur Iì anatoxine
diptheriques. Ann InstPasteur. 38, 1-10.
60. Virgil EJ Schijns (1999) Immunological concepts
of vaccine adjuvant activity. Curr. Opinion in
Immunol.12, 456-463.
61. Derek T and O’Hagan (1997) Recent advances
in vaccine adjuvants for systemic and mucosal
administration. J. Pharm. 49, 1-10.
62. Chopra N, Thomas BE, Sabhnani L and Rao D N
(2000) Inducing protective antibodies against
RESA peptide using modified delivery systems
“ISCOMs”. Med. Microbiol.Immunol. 18, 975-83.
63. Weidner J (2001) Adjuvancy enhancement by
modulated release from microspheres. Drug
Discov Today 6, 106.
64. Sridevi K, Manocha M, Sabhnani L, Thomas BE,
Rao DN (2000) New age adjuvants and delivery
systems for subunit vaccines. Ind.J. Clin.
Biochem. 15, 83-100.
65. Mestecky J, Moldoveanu Z, Michalek SM, Morrow
C, Compans RW, Schafer DP and Rusell MW
(1996) Current options for vaccine delivery
systems by mucosal routes. J. Control. Rel. 34,
567-572.
66. Gozales C, Home D , Noriega FR, Tacket C0, Davis
JR, Losonsky G, Nataro JP, Hofmann A and Levine
MM (1994) Salmonella typhi vaccine strain
CVD908 expressing these circumsporozoite
proteins of Plasmodium falciparum : Strain
construction and safety immunogenicity in
humans. J. infect. Dis.169, 927-931.
67. Manocha M, Pal PC, Chitralekha KT, Thomas BE,
Siddhartha DG, Paranjape R, and Kulakrni S and
Rao DN (2005) Enhanced mucosal and systemic
immune response with intranasal immunization
of mice with peptides entrapped in PLGA
microparticles in combination with Ulex
Europeaus-1 as compared to oral, rectal, or
Indian Journal of Clinical Biochemistry, 2005
69. Baca-Estrada ME, Foldvari MM, Snider MM,
Harding KK, Kournikakis BB, Babiuk LA and
Griebel PP (2000) Intranasal immunization with
liposome-formulated Yersinia pestis vaccine
enhances mucosal immune responses. Vaccine,
18, 2203-2211.
70. Burton KW, Shameem M, Thanoo BC and DeLuca
PP (2000) Extended release peptide delivery
systems through the use of PLGA microsphere
combinations. J.Biomater. Sci. Polym. Ed. 11, 715729.
71. Butler JE, Satam M and Ekstrand JE (1990)
Fluoride: an adjuvant for mucosal and systemic
immunity. Immunology letters 26, 217-220.
72. Tengerdy RP and Lacetera NG (1991) Vitamin E
adjuvant formulations in mice. Vaccine, 9, 204206.
73. Kaur J and Rao D N (1990) New approaches to
molecular vaccines. Natl. Med.J. Ind. 3, 58-63.
74. Jerne NK (1974) Towards a network theory of the
immune system. Ann. Inst. Pasteur Immunol.
125C, 373-389.
75. Sege K and Peterson PA (1978) Use of antiidiotypic antibodies as cell-surface receptor
probes. Proc Natl Acad Sci USA. 75, 2443-2447.
76. Gilboa E, Smita NK and Kim HL (1998)
Immunotherapy of cancer with dendritic-cell
based vaccines. Cancer Immunol.Immunother.
46, 82-87.
77. Steinman RM (1991) The dendritic cell system
and its role in immunogenicity. Annu. Rev.
Immunol. 9, 271-296.
78. Porgador A and Gilboa E (1995) Bone marrowgenerated dendritic cells pulsed with a class I restricted peptide are potent inducers of cytotoxic
T lymphocytes. J. Exp.Med. 182, 255-260.
79. Zitvogel L, Robbins PD, Strokus WJ, Clarke MR,
Maeurer MJ, Campbell RL, Davis CG, Tahara H,
Schreiber RD and Lotze MT (1996) Intrleukin-12
and B7.1 co-stimulation co-operate in the
induction of effective antitumour immunity and
229
Indian Journal of Clinical Biochemistry, 2005, 20 (1) 213-230
therapy of established tumours. Eur. J. lmmunol.
26, 1335-1341.
80. Kapusta J, Modelska A, Figlerowicz M, Pniewski
T, Letellier M, Lisowa 0, Yusibov V, Koprowski H,
Plucienniczak A and Legocki AB (1999) A plantderived edible vaccine against hepatitis B virus.
FASEB J. 13, 1796-1799.
81. Ronald WE (1999) Development of combination
vaccines. Vaccine, 17, 1635-1642.
82. Wolff JA, Dowty ME , Jiao S, Repetto G, Berg RK,
Ludtke JJ, Williams P and Slautterback DB (1992)
Expression of naked plasms by cultured
myotubes and entry of plasmids into T tubules
and caveolae of mammalian skeletal muscle. J
Cell Sci. 103, 1249-1259.
83. Li Z (1997) Priming of T cells by heat shock proteinpeptide complexes as the basis of tumor vaccines.
Semin. Immunol. 9, 315-322.
84. Yedavelli SPK, Guo L, Daou ME, Srivastava PK,
Mittelman A and Tiwari RK (1999) Preventive and
therapeutic effect of tumour derived heat shock
protein gp96 in an experimental prostate cancer
model. Int. J Molec. Med. 4, 243-248.
85. Chen CH, Wang TL, Hung CF, Yang Y, Young RA,
Pardoll DM and Wu TC (2000) Enhancement of
DNA vaccine potency by linkage of antigen gene
to an HSP70 gene. Cancer Res. 60, 1035-1042.
86. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK,
Xiao X and Chen SL.(2000) Recombinant adenoassociated
virus
expressing
human
papillomavirus type 16 E7 peptide DNA fused with
heat shock protein DNA as a potential vaccine for
cervical cancer. J. Vlrology. 74, 2888-2894.
87. Goldsmith GZ and Dhanasekaran N. (2004) The
Microrevolution: Applications and impacts of
microarray technology on molecular biology and
medicine (Review). Int. J. Mol. Med. 13, 483-495.
88. Kuhn E. (2001) From Library screening to
microarray technology: Strategies to determine
gene expression profiles and to identify
differentially regulated genes in plants. Annals of
Botany. 87, 139-155.
Clin.Infec.Dis. 30, 291-8.
91. Wang XY, Kaneko Y, Repasky E and Subjeck JR
(2000) Heat shock protein and cancer
immunotherapy. Immunol. Invest. 29, 131-137.
92. Akdis CA and Blaser K (2000) Regulation of
specific immune response by chemical and
structural modifications of allergens. Int. Arch.
Allergy, Immunol. 121, 261-269.
93. Masihi KN (2000) Immunomodulatory agents for
prophylaxis and therapy of infections. Int. J
Antimicrob Agents. 14, 181-191.
94. Roggero MA, Weilenmann C, Bonelo A, Audran R,
Renggli J, Spertini F, Corradin G and Lopez J
(1999) Plasmodium falciparum Cs C -terminal
fragment: preclinical evaluation and phase I
clinical studies. Parasitologia, 14, 421-424.
95. Nardin E, Zavala F, Nussenzweig V and
Nussenzweig RS (1999) Pre-erythrocytic malaria
vaccine: mechanisms of protective immunity and
human vaccine trials. Parasitologia, 41, 397 –
402.
96. Sela M (1999) Specific vaccines against
autoimmune diseases. C R Acad Sci III. 11933938.
97. Poalazzi CC, Perez 0 and De Filippo J (1999)
Rabies vaccine. Developments employing
molecular biology methods. Mol Biotechnol. 11,
137-147.
98. Yusibov V, Shivprasad S, Turpen T H, Dawson W
and Koprowski H (1999) Plant viral vectors based
on tobamoviruses. Curr Top Microbiol. immunol.
240, 81-94.
99. Singh M, Das SK, Suri S, Singh 0, Talwar G P
(1998) Regain of fertility and normality of progeny
born during below protective threshold antibody
titers in women immunized with the HSD-hCG
vaccine. Am. J. Reprod. Immunol. 39, 395-398.
100. Gupta SK, Jethanandani P, Afzalpurkar A, Kaul R
and Santhanam R (1997) Prospects of zona
pellucida glycoproteins as immunogens for
contraceptive vaccine. Hum. Reprod. Update, 3,
299-300.
89. Neuman de Vegvar HE. (2004) Microarray profiling
of antiviral antibodies form the developement of
diagnostics, vaccines and therapeutics. Clin.
Immunol. 111, 196-201.
101. Naz RK (2000) Fertilization-related sperm
antigens and their immunocontraceptive
potentials. Am. J. Reprod. Immunol. 44, 41-46.
90. Vordermeir HM, Cockle PJ, Whelan AO, Rhodes
S and Hewinson RG (2000) Toward the
development of diagnostic assays to discriminate
between mycobacterium bovis infection and
Bacilli Calmette Guerin vaccination in cattle.
102. Toes RE, Offringa R, Blom RJ, Melief CJ and Kast
WM (1996) Peptide vaccination can lead to
enhanced tumor growth through specific T-cell
tolerance induction. Proc. Natl. Acad. Sci. USA.
93, 7855-7860.
Indian Journal of Clinical Biochemistry, 2005
230